Inside Washington: The Big Shift

March 15, 2003

Jill Wechsler

Jill Wechsler

Jill Wechsler is BioPharm International's Washington Editor, jillwechsler7@gmail.com.

BioPharm International, BioPharm International-03-01-2003, Volume 16, Issue 3

Jill Wechsler FDA explains its plan for moving most biologics under the authority of CDER. But a big question remains: What will the change do to approval times?

Related Content:

Biotech World: India Blossoms

Outsourcing Outlook: One-Stop Shops

Qualification of a Chromatographic Column: Why and How to Do It